drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
Gene-modified natural killer cells engineered ex vivo to express a chimeric antigen receptor targeting CD19; given as a single IV infusion to induce NK-mediated cytotoxicity against CD19+ B-cell malignancies.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Natural Killer Cells
drug_category
CAR NK
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Ex vivo gene-modified natural killer cells engineered to express a CD19-specific chimeric antigen receptor; CAR engagement of CD19 activates NK signaling (CD3zeta/costimulatory domains) to drive targeted lysis of CD19+ B cells via perforin/granzyme release and cytokine secretion.
drug_name
CD19-directed CAR-NK cells
nct_id_drug_ref
NCT06596057